Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Aug 28, 2012

Top 25 Biotech Companies

Did your company make the list?

Top 25 Biotech Companies

These firms are currently doing the best in the business, based on market capitalization at the end of Q2 2012, and Q2 2011. [© Lane Erickson - Fotolia.com]

  • #15. Elan

    2012 Market Cap: $8.63 billion (6/30: 591.3 million shares *price $14.59)

    2011 Market Cap: $6.67 billion (6/30: 586.4 million shares *price $11.37)

    % Change: 29.4%

  • #14. UCB

    2012 Market Cap: $8.77 billion (6/30: 179.1 million shares * price €39.84)

    2011 Market Cap: $6.84 billion (6/30: 179.5 million shares * price €30.99)

    % Change: 28.2%

  • #13. Forest Laboratories

    2012 Market Cap: $8.87 billion (8/8: 265,693,834 shares * price $33.40)

    2011 Market Cap: $9.09 billion (8/8: 274,555,930 shares * price $33.12)

    % Change: -2.4%

  • #12. Regeneron

    2012 Market Cap: $11.30 billion (7/13: 96,044,622 shares * price $117.64)

    2011 Market Cap: $5.09 billion (7/15: 91,626,617 shares * price $55.59)

    % Change: 122.0%

  • #11. Vertex Pharmaceuticals

    2012 Market Cap: $10.64 billion (7/27: 215,807,482 shares * price $49.32)

    2011 Market Cap: $10.79 billion (7/29: 208,087,899 shares * price $51.86)

    % Change: -1.4%

  • #10. Alexion

    2012 Market Cap: $18.85 billion (7/24: 193,059,462 shares * price $97.62)

    2011 Market Cap: $10.48 billion (7/29: 184,530,093 shares * price $56.80)

    % Change: 79.9%

  • #9. CSL

    2012 Market Cap: $21.11 billion (A$20.099 billion)

    2011 Market Cap: $18.33 billion (A$17.454 billion)

    % Change: 15.2%

  • #8. Merck KGaA

    2012 Market Cap: $21.16 billion (6/30: 217,388,939 shares * price €78.72)

    2011 Market Cap: $20.14 billion (6/30: 217,388,939 shares * price €74.94)

    % Change: 5.1%

  • #7. Celgene

    2012 Market Cap: $28.38 billion (7/23: 431,423,976 shares * price $65.78)

    2011 Market Cap: $27.52 billion (7/26: 458,805,956 shares * price $59.99)

    % Change: 3.1%

  • #6. Baxter

    2012 Market Cap: $32.27 billion (7/30: 547,231,164 shares * price $58.97)

    2011 Market Cap: $33.36 billion (7/28: 568,256,444 shares * price $58.70)

    % Change: -3.3%

  • #5. Teva Pharmaceutical Industries

    2012 Market Cap: $34.23 billion (6/30: 868,000,000 shares * price $39.44)

    2011 Market Cap: $42.96 billion (6/30: 891,000,000 shares * price $48.22)

    % Change: -20.3%

  • #4. Biogen Idec

    2012 Market Cap: $34.26 billion (7/18: 236,346,955 shares * price $144.96)

    2011 Market Cap: $25.60 billion (7/22: 242,545,771 shares * price $105.56)

    % Change: 33.8%

  • #3. Gilead Sciences

    2012 Market Cap: $40.16 billion (7/20: 756,568,507 shares * price $53.08)

    2011 Market Cap: $32.68 billion (7/29: 771,455,146 shares * price $42.36)

    % Change: 28.5%

  • #2. Amgen

    2012 Market Cap: $60.09 billion (7/25: 770,768,879 shares * price $77.96)

    2011 Market Cap: $49.72 billion (7/27: 924,091,356 shares * price $53.80)

    % Change: 20.9%

  • #1. Novo Nordisk

    2012 Market Cap: $76.92 billion (6/30: DKK 549.1 million * price DKK 848.50)

    2011 Market Cap: $60.09 billion (6/30: DKK 569.1 million * price DKK 639.50)

    % Change: 28.0%

  •  

    Leave a comment by clicking the “Comments” icon. We want to hear your thoughts!



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »